Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credit: iStock/ UKHSA
The UK Health Security Agency (UKHSA) has issued a red heat-health alert across the Midlands and southern England until June 25, warning that extreme temperatures could pose a risk to everyone's health—not just vulnerable groups.
The alert, the highest level in the UK's heat warning system, comes as temperatures continue to rise and authorities warn of potential health emergencies, travel disruption and strain on critical infrastructure.
"Red heat health alert issued for East of England, East Midlands, London, South East, South West, and West Midlands. An amber heat health alert was issued for the North East, North West, and Yorkshire and The Humber," the agency said.
The UKHSA warned that many people struggle in hot weather and reminded the public that heat-related illnesses can become serious very quickly.
"Heat exhaustion and heatstroke are serious and potentially life-threatening conditions," the agency said in a post on X.
A red warning is the most severe level of heat alert issued by UK authorities. It indicates:
The warning is scheduled to remain in force from 09:00 BST on June 24 until 21:00 BST on June 25. The Met Office has advised people to avoid unnecessary travel where possible and follow guidance from emergency services and local authorities.
This is only the second time such a warning has been issued since the UK's extreme heat warning system was introduced in 2021. The first red heat warning was issued during the record-breaking heatwave of July 2022.
As temperatures climb, several schools across western England have announced early closures due to concerns about pupils and staff spending prolonged periods in overheated classrooms, the BBC reported.
Also read: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries
The NHS says heat exhaustion usually improves if a person cools down within 30 minutes.
Common symptoms include:
Heatstroke is a medical emergency and requires immediate treatment.
Warning signs include:
Health officials recommend taking the following precautions during periods of extreme heat:
Older adults, young children, pregnant women and people with long-term conditions such as diabetes or heart disease are at greater risk of heat-related illness.
The NHS urged people to regularly check on family members, neighbors and friends who may need assistance during extreme temperatures.
Credit: iStock
In a landmark medical achievement, NYU Langone Health in the United States has successfully carried out the world's first lung transplant from an HIV-positive donor to an HIV-positive recipient.
Researchers described the procedure carried out on 56-year-old Bertrand Nelson, living with HIV for nearly 26 years, as a "watershed moment for the HIV-positive community". They noted that the medical feat could significantly expand the pool of organ donors available to people living with HIV.
"While these transplants are still only allowable under certain research protocols, this marks an expansion of options for people in need of a lifesaving organ," said Sapna Mehta, Clinical Director of the NYU Langone Transplant Institute.
Also read: HIV No Longer Barrier To Organ Transplants, Say Delhi Doctors After Successful Kidney Surgery
The transplant was performed under research protocols established through the 2013 HIV Organ Policy Equity (HOPE) Act, which allows organs from HIV-positive donors to be transplanted into HIV-positive recipients in approved research settings.
According to the researchers, while HIV-positive donor transplants involving hearts and abdominal organs have been performed previously, this was the first time such a procedure was successfully carried out for the lungs.
"Transplantation of hearts and abdominal organs has been done before, but this has not been done in lung transplantation," said Mark A. Sonnick, transplant pulmonologist at NYU Langone Transplant Institute.
Approximately 1.2 million people in the United States are living with HIV. Thanks to modern antiretroviral therapy (ART), most people with HIV can now live long, healthy lives, have near-normal life expectancy, and are unable to transmit the virus when treatment is effective.
Nelson was diagnosed with both HIV and sarcoidosis, an inflammatory disease that can affect multiple organs, particularly the lungs, in 2000. At the time, doctors said the condition was in remission.
However, in 2021, Nelson contracted Legionnaires' disease, a severe form of pneumonia that required weeks of hospitalization. The illness reactivated his sarcoidosis, which subsequently spread to his liver.
By 2024, his condition had deteriorated significantly. He required increasing amounts of oxygen to breathe and was referred to the NYU Langone Transplant Institute for evaluation for both lung and liver transplantation.
Following assessment under the HOPE Act research program, Nelson was approved for a dual-organ transplant.
On March 21, surgeons transplanted both a new set of lungs and a new liver during the same operation, making medical history.
Read More: Australia’s H5N1 Detection Marks End Of Last Virus-Free Continent
In a statement, NYU Langone said Nelson is doing well after the complex surgery.
"Nelson is now off oxygen for the first time in four years and getting back in shape after years of limited mobility," the statement read.
Nelson credited his mother, who will turn 82 in August, for her unwavering support throughout his health struggles.
"I want to be well for her," Nelson said. "I want her to see me thriving."
Nelson hopes his experience will encourage others and draw attention to the need for greater access to organ transplantation within the HIV community.
"There are so many others who need access to this level of care, and the more organs that become available, the better the odds of finding the right match and living a long life," he said.
As per the US National Institutes of Health, people with HIV can successfully donate or receive transplanted organs with reasonable success rates.
However, health care providers must consider and monitor potential drug interactions, kidney and liver function, and HIV viral suppression in people with HIV receiving a transplant. Further, the NIH advised HIV positive patients to continue taking all prescribed HIV medicines before and after transplant.
Credit: iStock
The ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) has surpassed 1,000 confirmed cases, according to the latest update from the country's Health Ministry.
In a statement posted on X, the ministry said as of June 20, the outbreak has resulted in 1,003 confirmed cases and 254 deaths, with a case fatality rate of 25.3 per cent
More than 100 people have recovered from the disease, while 365 patients are currently in isolation or receiving hospital treatment.
"The threshold of 1,000 confirmed cases has been crossed. Despite this progression, response teams continue active investigations, epidemiological surveillance, and prevention actions in affected areas," the ministry said.
"The response to the Ebola virus disease continues in the provinces of Ituri, North Kivu, and South Kivu, with an improvement in the number of recoveries but a decrease in the contact follow-up rate," the ministry added.
Also read: Australia’s H5N1 Detection Marks End Of Last Virus-Free Continent
The outbreak is also taking a growing toll on healthcare workers. According to the DRC's National Public Health Institute, at least 78 nurses, doctors, and other healthcare workers have contracted the disease during the outbreak, and 18 have died.
Abdou Sebushishe, medical lead in Congo for the International Medical Corps, said all infected healthcare workers were exposed outside dedicated Ebola treatment facilities, Bloomberg reported.
The current outbreak involves the Bundibugyo strain of Ebola, which often begins with symptoms similar to malaria and other common illnesses.
Because early symptoms can be difficult to distinguish, healthcare workers may come into contact with infected patients before Ebola is suspected and strict infection-control measures are implemented.
Sebushishe said infections among healthcare workers have been linked to several factors, including:
Meanwhile, Israel's Health Ministry has reported two suspected Ebola cases involving individuals who recently returned from Congo.
Officials stressed that Ebola infection has not yet been confirmed, and laboratory testing is underway. Results are expected in the coming days, according to local media reports.
The ministry said it is conducting an epidemiological investigation to identify contacts and assess any potential links between the suspected cases.
According to the Health Ministry, Israel has never recorded a confirmed Ebola case. During the major West African Ebola outbreak in 2014, several suspected cases were investigated, but all ultimately tested negative.
Read More: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries
Ebola is a severe and often fatal viral hemorrhagic fever first identified in 1976. Since then, more than 30 outbreaks have been recorded, primarily in Central and West Africa.
Common symptoms include:
In severe cases, the disease can lead to organ failure, internal bleeding, shock, and death. Aid organizations warn that without stronger surveillance, expanded testing, faster laboratory turnaround times, and more effective contact tracing, the outbreak could continue to grow in the coming weeks and months.
© 2024 Bennett, Coleman & Company Limited